In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:

• Key data supporting the clinical use of these agents
• Optimal sequencing and timing of use
• Dosing considerations
• Key adverse events

Presenters:

Joleen Hubbard, MD
Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Link to full program:  BITLY NEEDED

 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.